Study | Eyes | Follow-up | Preop SEQ (D) | Postop SEQ (D) | ±0.50 D | 20/20 CDVA preop | UDVA 20/20 or better postop | UDVA 20/25 or better postop | Loss 2 lines CDVA |
---|---|---|---|---|---|---|---|---|---|
Sekundo 2011 [11] | 91 | 6 months | −4.75 ± 1.56 | −0.01 ± 0.49 | 80% | --- | 84% | 92% | 1.1% |
Shah 2011 [12] | 51 | 6 months | −4.87 ± 2.16 | +0.03 ± 0.30 | 91% | 67% | 62% | 79% | 0.0% |
−1.75 to −10.00 | −0.75 to +0.75 | ||||||||
Vestergaard 2012 [17] | 127 | 3 months | −7.18 ± 1.57 | −0.09 ± 0.45 | 77% | --- | 37% | 73% | 0.4% |
−1.63 to −11.50 | −1.63 to +1.38 | ||||||||
Hjortdal 2012 [13] | 670 | 3 months | −7.19 ± 1.30 | −0.25 ± 0.44 | 80% | 88% | 61% | 84% | 2.4% |
−1.63 to −9.88 | −2.13 to +1.38 | ||||||||
Wang 2013 [18] | 88 | 3 months | --- | −0.11 ± 0.29 | --- | --- | 100% | --- | 0.0% |
Kamiya 2014 [19] | 26 | 6 months | −4.21 ± 1.63 | +0.01 | 100% | 100% | 96% | --- | 0.0% |
−1.25 to −8.25 |  | ||||||||
Sekundo 2014 [20] | 54 | 1 year | −4.68 ± 1.29 | −0.19 ± 0.19 | 92% | 98% | 88% | 98% | 0.0% |
−2.00 to −9.00 | −1.00 to +0.50 | ||||||||
Agca 2014 [21] | 40 | 1 year | −4.03 ± 1.61 | −0.33 ± 0.25 | 95% | --- | 65% | 95% | 0.0% |
Lin 2014 [22] | 60 | 3 months | −5.13 ± 1.75 | −0.09 ± 0.38 | --- | --- | 85% | 93% | 1.7% |
−1.75 to −7.75 | −1.25 to +0.75 |